Onxeo Sa Stock Profit Margin
| C4X Stock | EUR 0.07 0 4.20% |
Onxeo SA fundamentals help investors to digest information that contributes to Onxeo SA's financial success or failures. It also enables traders to predict the movement of Onxeo Stock. The fundamental analysis module provides a way to measure Onxeo SA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Onxeo SA stock.
Onxeo |
Onxeo SA Company Profit Margin Analysis
Onxeo SA's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Onxeo SA has a Profit Margin of 0.0%. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The profit margin for all Germany stocks is 100.0% lower than that of the firm.
Onxeo Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Onxeo SA's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Onxeo SA could also be used in its relative valuation, which is a method of valuing Onxeo SA by comparing valuation metrics of similar companies.Onxeo SA is currently under evaluation in profit margin category among its peers.
Onxeo Fundamentals
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 111.06 M | |||
| Shares Owned By Insiders | 13.25 % | |||
| Shares Owned By Institutions | 12.72 % | |||
| Price To Earning | 50.90 X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 5.35 X | |||
| Revenue | 4.06 M | |||
| Gross Profit | 3.69 M | |||
| EBITDA | (4.49 M) | |||
| Net Income | (5.94 M) | |||
| Cash And Equivalents | 24.46 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 9.91 M | |||
| Debt To Equity | 0.31 % | |||
| Current Ratio | 3.85 X | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (8.57 M) | |||
| Earnings Per Share | (0.11) X | |||
| Number Of Employees | 36 | |||
| Beta | 1.89 | |||
| Market Capitalization | 37.98 M | |||
| Total Asset | 53.06 M | |||
| Z Score | 1.8 | |||
| Net Asset | 53.06 M |
About Onxeo SA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Onxeo SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Onxeo SA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Onxeo SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Onxeo Stock
Onxeo SA financial ratios help investors to determine whether Onxeo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Onxeo with respect to the benefits of owning Onxeo SA security.